Eli Lilly and Company (LLY)
What Are The Biggest Risks To Eli Lilly Stock?
Eli Lilly stock (LLY) is currently trading near $1,000, reflecting a decline of over 11% from its 52-week high as investors recalibrate expectations against emerging headwinds.
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?
LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. The "Employer Connect" platform gives employers more flexibility in how they cover obesity treatments, aiming to broaden employee access to the drugs at low out-of-pocket costs, while also keeping costs within budgets.
Forget AI. This Biotech Stock's Taking Off Right Now
The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings, all while the question marks surrounding ROIs get bigger.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata
Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.
What Smart Money Loves About Lilly
Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Danish company's next-generation obesity drug.
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug.
